Last reviewed · How we verify

NCT02589288

Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus For Postoperative Analgesia After Day-Case Anterior Cruciate Ligament Reconstruction

Completed NA Last updated 11 August 2017
What this trial tests

NA trial testing Continuous Infusion of ropivacaine 0.2% in Injury of Anterior Cruciate Ligament in 80 participants. Completed in 1 March 2017.

Timeline
1 November 2015
Primary endpoint
1 December 2016
1 March 2017

Quick facts

Lead sponsorASST Gaetano Pini-CTO
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment80
Start date1 November 2015
Primary completion1 December 2016
Estimated completion1 March 2017
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

ASST Gaetano Pini-CTO — full company profile →

Who can join

18 and older, any sex, with Injury of Anterior Cruciate Ligament. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The aim of this prospective, randomized , blinded study is to compare two different infusion techniques (continuous VS intermittent automatic bolus) to assess the effects of postoperative analgesia after Day-Case anterior cruciate ligament (ACL) reconstruction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other ASST Gaetano Pini-CTO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02589288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing